Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aethlon Medical Inc (AEMD)
NASDAQ:AEMD
Holding AEMD?
Track your performance easily
AEMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.24 - $2.35
Previous Close$0.58
Volume71.87M
Average Volume (3M)2.35M
Market Cap
$6.05M
Enterprise Value-$9.49K
Total Cash (Recent Filing)$6.86M
Total Debt (Recent Filing)$798.45K
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Feb 17, 2025EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.85
Shares Outstanding13,961,998
10 Day Avg. Volume5,909,650
30 Day Avg. Volume2,348,242
Standard Deviation0.58
R-Squared0.03
Alpha-0.00259
Financial Highlights & Ratios
Price to Book (P/B)1.35
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Aethlon Medical News
PremiumCompany Announcements
Aethlon Medical Reports Progress in Oncology Trials
PremiumCompany Announcements
Aethlon Medical Advances Oncology Trials and Global Expansion
PremiumCompany Announcements
Aethlon Medical Appoints James B. Frakes as CEOBulls Say, Bears Say
Bulls Say
Clinical TrialsThe company is making progress with its clinical trials, having enrolled the first two patients in the Hemopurifier trial for cancer patients with solid tumors.
Ethics ApprovalsTwo hospitals in Australia are open for patient enrollment, and additional sites in Australia and India have received ethics committee approval.
Pre-Clinical DataAEMD has disclosed pre-clinical proof-of-concept data utility related to the Hemopurifier in reducing complications following organ transplantation by removing viruses and exosomes from the harvested organ.
Bears Say
Product ApprovalThere is uncertainty regarding the potential approval and commercialization of the Hemopurifier in the oncology and organ transplant markets.
RevenueThe company reported no revenue recognition for the quarter and does not forecast any revenue recognition for FY25 or FY26.
Stock RecommendationThe recommendation is to maintain a Hold rating and not to purchase AEMD shares at this time based on a balanced risk/reward analysis.
---
Ownership Overview
2.28% Insiders
0.29% Mutual Funds
0.12% Other Institutional Investors
97.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AEMD FAQ
What was Aethlon Medical Inc’s price range in the past 12 months?
Aethlon Medical Inc lowest stock price was $0.24 and its highest was $2.35 in the past 12 months.
What is Aethlon Medical Inc’s market cap?
Currently, no data Available
When is Aethlon Medical Inc’s upcoming earnings report date?
Aethlon Medical Inc’s upcoming earnings report date is Feb 17, 2025 which is in 58 days.
How were Aethlon Medical Inc’s earnings last quarter?
Aethlon Medical Inc released its earnings results on Nov 13, 2024. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.195 by -$0.005.
Is Aethlon Medical Inc overvalued?
According to Wall Street analysts Aethlon Medical Inc’s price is currently Overvalued.
Does Aethlon Medical Inc pay dividends?
Aethlon Medical Inc does not currently pay dividends.
What is Aethlon Medical Inc’s EPS estimate?
Aethlon Medical Inc’s EPS estimate is -$0.2.
How many shares outstanding does Aethlon Medical Inc have?
Aethlon Medical Inc has 13,961,998 shares outstanding.
What happened to Aethlon Medical Inc’s price movement after its last earnings report?
Aethlon Medical Inc reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.195. Following the earnings report the stock price went down -2.439%.
Which hedge fund is a major shareholder of Aethlon Medical Inc?
Currently, no hedge funds are holding shares in AEMD
---
Aethlon Medical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
AEMD Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.1%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.14%
12-Months-Change
Fundamentals
Return on Equity
-137.96%
Trailing 12-Months
Asset Growth
-31.03%
Trailing 12-Months
Company Description
Aethlon Medical Inc
Aethlon Medical, Inc. is a therapeutic technology company, which focuses on addressing global health and biodefense needs. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The firm operates through two segments: Aethlon and ESI. The Aethlon segment involves in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in May 1998 and is headquartered in San Diego, CA.
---
AEMD Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights Aethlon Medical's significant progress in oncology trials and successful expense reductions. However, financial challenges persist with a notable net loss, and there are delays in trial enrollments in India. Despite these concerns, the advancements in the oncology program and strategic cost management efforts are promising.Read More>---
AEMD Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering AEMD
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-68.38%
reiterated a buy rating 10 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -68.38% per trade.
---